Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.

PLoS Med · 2022 · PMC9182592 · PMID 35613184

Europe PMC DOI

hedged sentence

0.0090

closest p · 0.2× alpha

0.0090

boldest claim

The sentences

highly significantp = 0.009actually significant

This difference was most evident in the earlier stage group (stage 1 to 2) with median overall survival of 30.0 months (95% CI: 26.4 to 35.1 months) in the warfarin group compared to 23.7 months (95% CI: 19.6 to 31.8 months) in the DOAC group, yielding a highly significant HR of 1.24 (95% CI: 1.06 to 1.45, p = 0.009).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.